Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL30658440 | 1.00 | ADRA2B (0.54) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL10675561 | 0.87 | SLC6A2 (0.69) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL19203471 | 0.87 | SLC6A2 (0.69) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| Cadaverine Tartrate SCHEMBL28556768 | 0.76 | MEN1 (0.50) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL17275362 | 0.76 | KMT2A (0.49) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL7996485 | 0.76 | MEN1 (0.57) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL7780731 | 0.76 | MMP2 (0.55) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL16932332 | 0.76 | KMT2A (0.49) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL304672 | 0.76 | MMP2 (0.55) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL28150189 | 0.76 | KMT2A (0.49) | HPGDKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255404-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10696654-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696654-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885SLC6A2 437/4885 |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885SLC6A2 437/4885 |
| US-20200255404-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | ADRA2B 200/4885ADRA2C 148/4885SLC6A2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.